Return of Results of Pharmacogenomic Testing for Genes Involved in Metabolism of 5FU and Capecitibine


About this study

A group of Mayo Clinic Biobank participants were genotyped for genetic variants as part of a separate study and a subset were found to be carriers of one or more important variants that increased risk of severe (grade 3, 4 or 5) toxicity.   

These variants were reviewed by experts at Mayo Clinic and judged to:  1) have important health implications (toxicity) for participants if they were ever exposed to pharmaceutical agents containing 5-fluoruracil, and 2) to be clinically actionable (change options for treatment).

The purpose of this study is to return results to participants enrolled in the Mayo Clinic Biobank (IRB 08-007049) who are known to carry genetic variants likely to cause toxicity if exposed to 5FU or capecitibine. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Participants in the Mayo Clinic Biobank (IRB 08-007049) who were genotyped for genes involved in the metabolism of 5FU and capecitibine.

Exclusion Criteria:

  • None.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Janet Olson, Ph.D.

Closed for enrollment

Contact information:

Jamison Odiet CRAT

(507) 266-0206

More information


Publications are currently not available

Mayo Clinic Footer